Ilkka M. Kantola

Turku, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Genetics, cardiac phenotype and cardiovascular outcomes in Fabry disease patients in Finland.

Genetics, cardiac phenotype and cardiovascular outcomes in Fabry disease patients in Finland.

Journal: ESC heart failure

Published: January 24, 2025

Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney.

Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney.

Journal: Blood pressure

Published: June 24, 2024

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

Screening and management of hypertensive patients with chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. A pilot survey based on questionnaire.

Journal: Journal of hypertension

Published: May 15, 2024

Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis.

Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis.

Journal: Journal of inherited metabolic disease

Published: December 22, 2023

Hemodynamic Bedside Monitoring Instrument with Pressure and Optical Sensors: Validation and Modality Comparison.

Hemodynamic Bedside Monitoring Instrument with Pressure and Optical Sensors: Validation and Modality Comparison.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 14, 2023

Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF).

Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF).

Journal: Primary care diabetes

Published: June 19, 2023

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.

Journal: Journal of medical genetics

Published: June 02, 2023

Development and clinical validation of a miniaturized finger probe for bedside hemodynamic monitoring.

Development and clinical validation of a miniaturized finger probe for bedside hemodynamic monitoring.

Journal: iScience

Published: January 31, 2023

Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study.

Long-term effectiveness of enzyme replacement therapy in Fabry disease with the p.Arg227Ter variant: Fabry disease in Ostrobothnia (FAST) study.

Journal: American journal of medical genetics. Part A

Published: January 28, 2023

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation.

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation.

Journal: Open heart

Published: January 04, 2023

An expert consensus on the recommendations for the use of biomarkers in Fabry disease.

An expert consensus on the recommendations for the use of biomarkers in Fabry disease.

Journal: Molecular genetics and metabolism

Published: December 09, 2022

Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.

Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.

Journal: Molecular genetics and metabolism

Published: July 30, 2022

Showing 1-12 of 55

Last Updated: 09/26/2026